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 Introduction 
 A nerve in the peripheral nervous system is a cord-like struc-
ture that contains many axons. It includes neurons and non-
neuronal Schwann cells that coat the axons in myelin. Myelin 
is an electrically insulating material and forms a sheath around 
the axon, which is fundamental for the proper conduction and 
transmission of electrochemical impulses, by insulating the 
axons from electrically charged atoms and molecules. Complete 
nerve injury (neurotmesis) results in the death of both dis-
tal axons and Schwann cells (i.e., those cells responsible to 
supply the myelin for peripheral neurons) with consequent 
functional loss in innervated organs. In contrast to the central 
nervous system, the peripheral nervous system has relevant 
regenerative capability, although complete functional recov-
ery is rarely reached. There are a large number of different cell 
types involved in the healing and regeneration of an injured 
nerve; for example, in a peripheral nerve lesion, the axon 
distal from the injury site degenerates, and Schwann cells and 
later macrophages clean the neural tubes of cell debris and 
myelin, so-called Wallerian degeneration.  1  Myelin is a layer 
of membranous structure around axons responsible for the fast 
and effi cient propagation of electrical impulses through the 
neural system. 
 When an injury occurs, a gap between the nerve’s dam-
aged ends is produced, and surgical intervention is necessary. 
Nowadays, there are two main strategies for those injuries 
with a long gap. In the fi rst strategy, synthetic or biological 
conduits are sutured to each stump in order to target the distal end, 
avoiding scar tissue infi ltration. A second approach to long gaps 
uses autologous nerve grafts (autografts) to provide a natural 
guidance channel populated with functioning Schwann cells, 
but this is challenging due to donor site collateral effects and 
patient condition.  2 , 3  Because the axon regrows quite slowly 
(about 2–5 mm per day), it is extremely important to accelerate 
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the regeneration time or to expand the time window of oppor-
tunity. To reach these goals, current experimental strategies 
include the usage of neurotrophins (proteins that regulate the 
development, maintenance, and function of neurons), growth 
factors, neurotransmitters, extracellular matrix proteins, and 
cell therapies mainly based on the use of Schwann cells and 
mesenchymal stem cells.  4  
 In the last decade, we have seen nanoscience gain increas-
ing control over the design, synthesis, and application of 
nanomaterials to nanodevices, starting what we recognize as 
nanotechnology. Nanostructured materials constitute a set of 
potential new therapies for neuroprotective and neuroregener-
ative purposes. These new therapies based on nanotechnology 
will require the ability to fabricate, characterize, and function-
alize a variety of nano-objects adapted to each specifi c need.  5 , 6  
One main purpose of these bio-nanotechnological approaches 
is to transform current scaffold strategies into a more precise 
way to control both physical and biological signals promot-
ing nerve regeneration.  7  Furthermore, as these materials pro-
vide new tools for neural therapies, they inspire new ways 
to improve care for patients with nervous system disorders.  8  
This review provides a general overview of how the magnetic 
properties of magnetic nanoparticles (MNPs) has been recently 
exploited in this fi eld. 
 Magnetic forces 
 The physical basis of remote (magnetic) actuation requires the 
use of a magnetic, “pulling” agent to interact with (i.e., the 
magnetic nanoparticles). When placed in a magnetic fi eld  B , 
the energy of a magnetic nanoparticle with magnetic (dipole) 
moment  m is given by  U = − m ∙  B , from which the force on 
the MNP performed by the fi eld can be extracted:
 ( ).= ∇ ⋅F m B  (1) 
 It follows from  Equation 1 that the force has a maximum value 
along the direction of the fi eld gradient. For decades, there 
have been efforts to use the principle contained in  Equation 1 
to generate magnetic forces capable of moving small (micron- or 
nano-sized, depending on the available technologies at each 
time) magnetic objects. The biological interest in this property 
resulted, for example, in highly effi cient protocols used rou-
tinely for magnetic cell separation. There are many theoretical 
calculations on the minimum values of magnetic forces that 
should be generated in order to manipulate NPs within the 
cytoplasm. However, these estimations are based on “nude” 
particles and an opsonization process in a biological medium. 
In this process, the particles are coated with different compo-
nents (e.g., albumin, IgG, apolipoproteins) of the biological 
medium, which change their hydrodynamic size, making the 
required forces much larger. 
 There is consensus that magnetic forces in the range of 0.1 
to 1 pN are enough to move MNPs through a moderately dense 
biological medium. Previous reports on magnetic manipulation 
have shown successful actuation in 2D systems using forces 
of 8–16 pN.  9 , 10  Also, recent experiments on magnetically guided 
neural growth have shown that fi eld gradients of 45 T/m are 
enough to obtain positive results regarding  in vitro neural ori-
entation.  7  Direct physiological effects from magnetic forces 
have also been reported. It has been recently proposed that 
mechanical stress can be produced by magnetic forces on cell 
structures. For example, the production of highly reactive ions 
and “free radicals” involving oxygen molecules, reactive oxygen 
species (ROS), can decrease the cell activity.  11  
 At room temperature, mechanical effects from thermal energy 
on nanometer-sized MNPs are relevant. The thermal energy 
 k B T (where  k B is the Boltzmann constant and  T is the tem-
perature) affects the magnetic behavior of MNPs due to the 
strong dependence of the magnetic relaxation time  τ N (Néel 
relaxation) on the particle’s volume  V through Arrhenius 
exponential decay . For example, a typical 30-nm magnetite 
MNP (i.e., diameter  d = 30 nm,  T = 300 K, effective mag-
netic anisotropy  K eff = 1.1 × 10 4 J/m 3 ) is expected to display 
a relaxation time  τ N = 2 × 10 6 s ( ∼ 24 days), and thus for any 
practical purpose, its magnetic moment is blocked. On the 
other side, similar MNPs having  d = 10 nm will relax within 
 τ N = 4.0 × 10 –10 s, and so for almost any experimental measur-
ing technique, the magnetization will average to zero in the 
absence of an applied magnetic fi eld. In the latter situation, 
it is said that the MNPs are in their superparamagnetic (SPM) 
state. The SPM state of a single domain particle implies null 
values of both the remanence  M R (i.e., magnetization value 
without magnetic fi eld) and the coercive fi eld  H C . 
 MNPs and cell interactions 
 At the cellular level, the interactions between nanomaterials 
and the neural system allowed us to understand many basic 
mechanisms of neural diseases,  12  and in some cases, some new 
ways to repair, replace, or augment the nervous system func-
tion.  13  For any specifi c application in biomedical sciences, the 
selection of MNPs is often determined by the physical proper-
ties of the magnetic material of the core constituting them, as 
well as the chemical/biological characteristics of the functional 
coating. Because they have already been approved for human 
use, iron-oxide NPs have been the most widely employed 
nanomaterial in biomedical studies so far. The magnetic cores 
possess the ability to remotely respond to external magnetic 
fi elds; this capacity has been exploited to manipulate NPs 
under external magnetic forces for targeting purposes, as well 
as for cell separation and labeling, drug delivery, and magnetic 
resonance imaging (MRI).  14  Moreover, the additional property 
of MNPs to absorb energy from time-varying magnetic fi elds 
has been used to induce cell death through heat generation in 
a new protocol known as magnetic hyperthermia.  15  
 Magnetic NPs can be produced by a number of physical 
and chemical methods that determine the fi nal properties of 
the product (see the November 2013 issue of  MRS Bulletin 
on “Magnetic Nanoparticles”). These properties are defi ned by 
the nanoparticle shape and size, the size distribution, and the 
surface chemistry of the resulting particles. The fi nal magnetic 
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properties of an ensemble of colloidal MNPs are strongly 
infl uenced by the degree of structural defects or impurities of 
the particle core and surface.  16  Synthesis methods described for 
iron-oxide NPs include co-precipitation, oxidative hydrolysis, 
microemulsions, and sol-gel reactions.  16 , 17  The effective use of 
MNPs for therapeutic purposes in biomedicine requires the use 
of a colloidal formulation. Because MNPs tend to aggregate 
due to their large surface-to-volume ratio and dipole-dipole 
interactions,  18  colloidal stabilization by surface modifi cation 
is required. Additional key requirements are biocompatibility 
of MNPs and chemical functionality for attachment of specifi c 
ligands or functional groups.  19 , 20  
 MNPs for neural guidance 
 The potential of magnetic materials for a non-invasive 
approach for nerve regeneration is related to the possibility of 
remote actuation of MNPs using an external magnetic fi eld. 
Specifi cally, MNPs can be forced along the direction of the 
external magnetic fi eld to induce projections of the cell body 
(called neurites) along the preferential direction. To improve 
the stability and biocompatibility, these kinds of MNPs can 
be coated with polymers, such as poly-L-lysine (PLL), which 
has been checked for the human neuroblastoma SH-SY5Y cell 
line and primary Schwann cell cultures of the peripheral ner-
vous system,  21  or polyethyleneimine (PEI) that was tested on 
neural models such as PC12 or SH-SY5Y cell lines.  22  
 Transmission electron microscopy (TEM) has been used 
to demonstrate that for these neural cell types, MNPs locate 
in the intracellular fl uid (cytosol) irrespective of the surface 
composition (see  Figure 1 ), but the amount of MNP uptake 
for a given surface composition is characteristic of each neu-
ral cell type. This fact has been exploited in  ex vivo studies 
on olfactory ensheathing cells (OECs) to remotely control the 
migration for regeneration of spinal cord injuries.  23  Multimodal 
iron-oxide NPs have been obtained by conjugation of the NPs 
with Rhodamine-B (MION-Rh) and have been studied  in vitro 
to label mesenchymal stem cells from umbilical cord blood 
(UC-MSC) to evaluate the proliferation kinetics by MRI.  24  
Furthermore, MNPs have been used as a magnetic carrier to 
cross the blood brain barrier (BBB), a protective membrane 
of the neural tissue from toxins, alien substances, and sudden 
changes in blood composition. Indeed, by functionalizing NPs 
with brain-derived neurotrophic factor (BDNF), it has been 
possible to demonstrate the effi cacy and ability of these nano-
vectors to cross the BBB for use as neuroprotectors.  25  
 Impact of iron-oxide MNPs on neural cells and 
the nervous system 
 The eff ects of biological media on iron-oxide MNPs 
 When NPs come in contact with biological fl uids, they adsorb 
proteins and other biomolecules. The formation of NP-protein 
complexes is commonly referred to as the NP-protein corona 
that can critically affect the interaction of NPs with living 
systems.  26  The proteins adsorbed onto NPs depend on many 
variables, including the biological medium and the physico-
chemical characteristics of the NPs (see the Fadeel et al. article 
in this issue).  27  
 There is consensus that the protein corona can infl uence 
the uptake of MNPs by cells, as well as their distribution and 
cytotoxicity. Moreover, this protein layer can modify the 
clearance, activity, and toxicity of MNPs through modifi ca-
tions in hydrodynamic size and surface charge.  28  Thus, the 
protein-NP interaction mechanisms must be known in order to 
effi ciently design MNPs that can target specifi c cell types.  29  
 Functionalization of NPs with appropriate polymers that 
provide appropriate functional groups for attachment of spe-
cifi c biological molecules, such as neurotrophic factors or cell 
recognition moieties, is important in the design of NPs for 
biomedical applications.  30 , 31  For instance, it has been recently 
shown that Fe 3 O 4 -based MNPs of similar size but with a 
different surface polymer coating (e.g., polyethyleneimine 
[PEI-MNPs] and poly(acrylic acid)-[PAA-MNPs]) strongly 
infl uence MNPs uptake by SH-SY5Y neuro-
blastoma cells, a tumor cell line of neural crest 
cell origin and an accepted model of neuro-
nal cell behavior. The study concluded that 
PEI-MNPs—that adsorbed larger amounts of 
proteins compared to PAA-MNPs—were inter-
nalized by the cells in a higher extent compared 
to PAA-MNPs.  28  
 The infl uence of MNP fi nal properties on 
the internalization mechanism and resulting 
intracellular distribution can be studied by 
scanning transmission electron microscopy 
that provides images with  Z -dependent intensity 
contrast ( Z being the atomic number of each 
element) so localization of MNPs within organ-
elles is facilitated. Application of this technique 
to the study of internalization pathways for 
different cell types is shown in  Figure 2 for 
PEI-MNPs and PAA-MNPs. It can be seen 
  
 Figure 1.  Typical transmission electron microscopy images of (a) PC12 and (b) SHSY5Y 
cells incubated with polyethyleneimine (PEI)-coated magnetic nanoparticles (MNPs) of 25 nm 
size. The different amounts of MNP uptake is a characteristic of each neural cell type. 
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that the intracellular distributions are different in the two 
cases due to the different protein corona compositions.  26  It is 
clear that MNP surface properties dictate the major biological 
properties and consequently the interaction with a given cell 
type. Understanding the dynamics of this complex interac-
tion is now recognized as the central requisite to better under-
stand the biological impact of these novel materials on living 
organisms. 
 Magnetically assisted neural growth and protection 
 The importance of mechanical factors for the nervous system 
has been appreciated only recently. The idea of tension being 
involved in the morphogenesis of the nervous system arose in 
the late 1970s, when experimental pioneering work revealed 
that neuronal processes of growing neurons  in vitro are under 
tension.  32  Later, it was demonstrated that the external appli-
cation of mechanical tension by glass needles alone is suf-
fi cient to initiate axonal outgrowth (i.e., axonal sprouting and 
lengthening).  33  There is thus some evidence that mechanical 
tension can even induce “stretch growth” of axons, and this 
mechanism can be exploited therapeutically.  34  
 Recently, Fass et al.  35  reported the use of magnetic beads to 
apply a tensile force and study its effect on neurite elongation. 
They were able to identify a force threshold of 15–100 pN. In 
addition to the evidence that mechanical tension can induce 
“stretch growth” of neurites or process initiation, its infl uence 
on axonal re-growth orientation has also been investigated. 
Recently, we reported the use of a MNP-based technique 
for the application of very low tension values (pN or below) 
on neuronal processes.  7  This study demonstrated, using the rat 
pheochromocytoma PC12 cell line, PC12 cell line that MNPs 
can be used to manipulate axons/neurites using external mag-
netic forces for controlled directional growth. Altogether, the 
existing literature indicates that forces generated by MNPs under 
static magnetic fi elds, when carefully controlled, could act as 
powerful stimulants of neuronal growth and development. 
 Conclusions 
 It is evident that magnetic nanoparticles 
are just beginning to reveal their potential as 
non-invasive agents for local actuation in dif-
ferent neurotherapies. The fi rst steps toward 
cell targeting using specifi c surface molecules 
have been realized, and now “fi ne tuning” of 
the surface chemistry is necessary in order to 
promote axon regeneration. Further progress 
on materials functionalization is also required 
for a more effi cient targeting of injured 
neural tissue, a pre-requisite for any magnet-
ically guided regeneration therapy. Although 
re-myelinating axons and removing inhibi-
tory factors are among the major problems yet 
to be solved, there is clear advancement on 
strategies for non-invasive guiding of neural 
cells and axonal regeneration. From a clinical 
applications perspective, much of the  in vitro 
proofs-of-concept are yet to be translated to the  in vivo fi eld 
in order to obtain the fi nal goal (i.e., to achieve full neuronal 
regeneration and restoration of lost neuronal functions after 
injury), allowing patients to recover both motor and physi-
ological functions. 
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